Chlamydia pneumoniae infection: an additional factor for chronic allograft rejection

Transplantation Proceedings
A KwiatkowskiW Rowiński

Abstract

Chronic rejection (CHR) of organ allografts, one of the most significant problems in modern transplantation, is not fully understood. This study sought to evaluate the influence of selected parameters on late kidney transplant function. The studied group consisted of eighty-six patients who received allogeneic transplants between 1988 and 1999 for leukocyte Chlamydia pneumoniae-DNA, immunoglobulin (Ig)A/IgG anti-C pneumoniae, blood lipids, ischemic damage in the donor and during organ preservation, HLA mismatch, and acute rejection episodes. Eighty-six patients were segregated as 26 patients (30%) with histologically proven chronic graft rejection (CHR[+]) and 59 patients (70%) without (CHR[-]). The presence of C pneumoniae-DNA in peripheral blood leukocytes was significantly more frequent in CHR(+) than CHR(-) group (46% vs 20%). Patients with leukocytes positive for C pneumoniae-DNA more frequently (50%) had CHR than patients negative for C pneumoniae-DNA (22%). CHR(+) patients showed significantly lower HDL levels (47 mg/dL vs 58 mg/dL) and higher triglyceride levels (193 mg/dL vs 148 mg/dL). To study the cumulative effect of differences between the CHR(+) and CHR(-) groups, we applied a multiple binary logistic regression a...Continue Reading

References

Dec 1, 1991·Annals of Surgery·E J SchweitzerJ S Najarian
Jun 23, 1989·JAMA : the Journal of the American Medical Association·M T GrattanN E Shumway
Aug 1, 1993·Immunological Reviews·P HäyryE Taskinen
Jan 1, 1994·Transplantation·H IsoniemiP Häyry
Apr 1, 1993·Transplantation·P S AlmondJ S Najarian
Jan 1, 1997·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·I LautenschlagerJ Ahonen
Feb 12, 2000·Transplantation·M M PolyakM Kinkhabwala
Mar 7, 2000·Journal of Transplant Coordination : Official Publication of the North American Transplant Coordinators Organization (NATCO)·J SzustL Cravero
May 17, 2000·Transplantation Proceedings·E RodrigoM Arias
Oct 21, 2000·Journal of Clinical Pathology·S A MorréH W Niessen
Nov 30, 2000·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·E RodrigoM Arias
Jan 1, 2003·The American Journal of Pathology·Immaculada Herrero-FresnedaJosep M Grinyo
Feb 24, 2004·Journal of the American Society of Nephrology : JASN·Martin GasserAnil Chandraker
Apr 20, 2004·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Hannah Valantine
Apr 30, 2005·Seminars in Vascular Medicine·Jon A Kobashigawa

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.